Literature DB >> 18456501

Total synthesis of phenanthroindolizidine alkaloids (+/-)-antofine, (+/-)-deoxypergularinine, and their dehydro congeners and evaluation of their cytotoxic activity.

Chung-Ren Su1, Amooru G Damu, Po-Cheng Chiang, Kenneth F Bastow, Susan L Morris-Natschke, Kuo-Hsiung Lee, Tian-Shung Wu.   

Abstract

Due to their limited natural abundance and significant biochemical effects, we synthesized the alkaloids (+/-)-antofine (1a), (+/-)-deoxypergularinine (1b), and their dehydro congeners (2 and 3) starting from the corresponding phenanthrene-9-carboxaldehydes. We also evaluated their in vitro cytotoxic activity. Compounds 1a and 1b showed significant potency against various human tumor cell lines, including a drug-resistant variant, with EC(50) values ranging from 0.16 to 16ng/mL. Structure-activity correlations of these alkaloids and some of their synthetic intermediates were also ascertained. The non-planar structure between the two major moieties, phenanthrene and indolizidine, plays a crucial role in the cytotoxic activity of phenanthroindolizidines. Increasing the planarity and rigidity of the indolizidine moiety significantly reduced potency. A methoxy group at the 2-position (1a) was more favorable for cytotoxic activity than a hydrogen atom (1b).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18456501      PMCID: PMC2577820          DOI: 10.1016/j.bmc.2008.04.032

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  13 in total

1.  Cytotoxic activity and G2/M cell cycle arrest mediated by antofine, a phenanthroindolizidine alkaloid isolated from Cynanchum paniculatum.

Authors:  Sang Kook Lee; Kyung-Ae Nam; Yoen-Hoi Heo
Journal:  Planta Med       Date:  2003-01       Impact factor: 3.352

2.  In vitro cytotoxic activity of phenanthroindolizidine alkaloids from Cynanchum vincetoxicum and Tylophora tanakae against drug-sensitive and multidrug-resistant cancer cells.

Authors:  Dan Staerk; Anne K Lykkeberg; Jette Christensen; Bogdan A Budnik; Fumiko Abe; Jerzy W Jaroszewski
Journal:  J Nat Prod       Date:  2002-09       Impact factor: 4.050

3.  First asymmetric total synthesis of (-)-antofine by using an enantioselective catalytic phase transfer alkylation.

Authors:  Sanghee Kim; Jaekwang Lee; Taeho Lee; Hyeung-geun Park; Deukjoon Kim
Journal:  Org Lett       Date:  2003-07-24       Impact factor: 6.005

4.  The interaction between tylophorine B and TMV RNA.

Authors:  Zhen Xi; Ruoyu Zhang; Zhihong Yu; Di Ouyang
Journal:  Bioorg Med Chem Lett       Date:  2006-06-12       Impact factor: 2.823

5.  Phenanthroindolizidine alkaloids from the stems of Ficus septica.

Authors:  Amooru G Damu; Ping-Chung Kuo; Li-Shian Shi; Chia-Ying Li; Chang-Sheng Kuoh; Pei-Lin Wu; Tian-Shung Wu
Journal:  J Nat Prod       Date:  2005-07       Impact factor: 4.050

6.  Synthesis and structure-activity studies of antofine analogues as potential anticancer agents.

Authors:  Ye Fu; Sang Kook Lee; Hye-Young Min; Taeho Lee; Jaekwang Lee; Maosheng Cheng; Sanghee Kim
Journal:  Bioorg Med Chem Lett       Date:  2006-09-30       Impact factor: 2.823

7.  Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines.

Authors:  L V Rubinstein; R H Shoemaker; K D Paull; R M Simon; S Tosini; P Skehan; D A Scudiero; A Monks; M R Boyd
Journal:  J Natl Cancer Inst       Date:  1990-07-04       Impact factor: 13.506

8.  Asymmetric total syntheses of (-)-antofine and (-)-cryptopleurine using (R)-(E)-4-(tributylstannyl)but-3-en-2-ol.

Authors:  Sanghee Kim; Taeho Lee; Eunjung Lee; Jaekwang Lee; Gao-jun Fan; Sang Kook Lee; Deukjoon Kim
Journal:  J Org Chem       Date:  2004-04-30       Impact factor: 4.354

9.  Expedient synthesis and structure-activity relationships of phenanthroindolizidine and phenanthroquinolizidine alkaloids.

Authors:  Ta-Hsien Chuang; Shiow-Ju Lee; Cheng-Wei Yang; Pei-Lin Wu
Journal:  Org Biomol Chem       Date:  2006-01-18       Impact factor: 3.876

10.  Structure-activity studies of phenanthroindolizidine alkaloids as potential antitumor agents.

Authors:  Wenli Gao; Scott Bussom; Susan P Grill; Elizabeth A Gullen; You-Cai Hu; Xueshi Huang; Sanbao Zhong; Conrad Kaczmarek; Julio Gutierrez; Samson Francis; David C Baker; Shishan Yu; Yung-Chi Cheng
Journal:  Bioorg Med Chem Lett       Date:  2007-05-16       Impact factor: 2.823

View more
  7 in total

1.  Synthesis of novel tylophorine derivatives and evaluation of their anti-inflammatory activity.

Authors:  Ti Wen; Ziwen Wang; Xianyi Meng; Meng Wu; Yangguang Li; Xiaoli Wu; Liqing Zhao; Puyue Wang; Zhinan Yin; Jesse Li-Ling; Qingmin Wang
Journal:  ACS Med Chem Lett       Date:  2014-07-23       Impact factor: 4.345

2.  Total synthesis of (+)-antofine and (-)-cryptopleurine.

Authors:  Weijiang Ying; James W Herndon
Journal:  European J Org Chem       Date:  2013-05-01

3.  Total syntheses of arylindolizidine alkaloids (+)-ipalbidine and (+)-antofine.

Authors:  Micah J Niphakis; Gunda I Georg
Journal:  J Org Chem       Date:  2010-09-03       Impact factor: 4.354

4.  Antitumor agents. 274. A new synthetic strategy for E-ring SAR study of antofine and cryptopleurine analogues.

Authors:  Xiaoming Yang; Qian Shi; Kenneth F Bastow; Kuo-Hsiung Lee
Journal:  Org Lett       Date:  2010-04-02       Impact factor: 6.005

5.  Phenanthroindolizidines and Phenanthroquinolizidines: Promising Alkaloids for Anti-Cancer Therapy.

Authors:  Sherry R Chemler
Journal:  Curr Bioact Compd       Date:  2009-03-01

6.  Synthesis, biological evaluation and mechanism studies of deoxytylophorinine and its derivatives as potential anticancer agents.

Authors:  Haining Lv; Jinhong Ren; Shuanggang Ma; Song Xu; Jing Qu; Zhenjia Liu; Qing Zhou; Xiaoguang Chen; Shishan Yu
Journal:  PLoS One       Date:  2012-01-19       Impact factor: 3.240

7.  In vitro anticancer effects of two novel phenanthroindolizidine alkaloid compounds on human colon and liver cancer cells.

Authors:  Jingjing Liu; Yu He; Dan Zhang; Ying Cai; Chenggang Zhang; Peng Zhang; Hongxia Zhu; Ningzhi Xu; Shufang Liang
Journal:  Mol Med Rep       Date:  2017-06-29       Impact factor: 2.952

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.